Dogwood Net Income From Continuing Ops from 2010 to 2024

DWTX Stock   2.40  0.20  7.69%   
Dogwood Therapeutics, Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -5.6 M in 2024. During the period from 2010 to 2024, Dogwood Therapeutics, Net Loss regression line of annual values had significance of  0.46 and arithmetic mean of (10,191,685). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-5.3 M
Current Value
-5.6 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Dogwood Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dogwood Therapeutics,'s main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 158.4 K or Interest Expense of 307.4 K, as well as many indicators such as . Dogwood financial statements analysis is a perfect complement when working with Dogwood Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Dogwood Therapeutics, Correlation against competitors.
For more information on how to buy Dogwood Stock please use our How to Invest in Dogwood Therapeutics, guide.

Latest Dogwood Therapeutics,'s Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Dogwood Therapeutics, over the last few years. It is Dogwood Therapeutics,'s Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dogwood Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Dogwood Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(10,191,685)
Coefficient Of Variation(23.92)
Mean Deviation1,270,205
Median(10,346,395)
Standard Deviation2,437,506
Sample Variance5.9T
Range10.7M
R-Value0.21
Mean Square Error6.1T
R-Squared0.04
Significance0.46
Slope113,709
Total Sum of Squares83.2T

Dogwood Net Income From Continuing Ops History

2024-5.6 M
2023-5.3 M
2022-12.2 M
2021-16 M

About Dogwood Therapeutics, Financial Statements

Dogwood Therapeutics, investors use historical fundamental indicators, such as Dogwood Therapeutics,'s Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dogwood Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-5.3 M-5.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Dogwood Stock Analysis

When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.